+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Gastroduodenal mucosal injury in patients taking low-dose aspirin and the role of gastric mucoprotective drugs: possible effect of rebamipide



Gastroduodenal mucosal injury in patients taking low-dose aspirin and the role of gastric mucoprotective drugs: possible effect of rebamipide



Journal of Clinical Biochemistry and Nutrition 47(1): 27-31



The present study was conducted to investigate the prevalence of mucosal injury in patients taking low-dose aspirin in Japan and examine the effect of gastric mucoprotective drugs on aspirin-related gastroduodenal toxicity. We selected 530 patients who had taken low-dose aspirin for 1 month or more after undergoing esophagogastroduodenoscopy from 2005 through 2006 at Teikyo University Hospital, Tokyo, Japan. Endoscopic records were retrospectively reviewed to determine the presence of massive bleeding and mucosal injury (ulcer or erosion). The influence of clinical factors, including co-administration of gastroprotective drugs, was also examined. Hemorrhage was observed in 25 patients (3.7%) and mucosal injury (36.2%) in 192 patients. The presence of Helicobacter pylori antibody was a significant risk factor associated with mucosal injury. Patients taking any gastroprotective drug showed a significantly lower rate of mucosal injury than those not taking these drugs. Patients taking rebamipide concomitantly with proton pump inhibitors or histamine 2 receptor antagonists had mucosal injury less frequently than those taking acid suppressants plus other mucoprotective drugs. In conclusion, these results show the possible gastroprotective effects of rebamipide, suggesting that it may be a good choice in aspirin users with gastroduodenal toxicity that is not suppressed by acid suppressants alone.

(PDF emailed within 0-6 h: $19.90)

Accession: 053353772

Download citation: RISBibTeXText

PMID: 20664727

DOI: 10.3164/jcbn.09-103


Related references

Determination of the adequate dosage of rebamipide, a gastric mucoprotective drug, to prevent low-dose aspirin-induced gastrointestinal mucosal injury. Journal of Clinical Biochemistry and Nutrition 59(3): 231-237, 2016

Does rebamipide prevent gastric mucosal injury in patients taking aspirin and clopidogrel?. Digestive Diseases and Sciences 59(8): 1671-1673, 2014

Effect of aspirin cessation before endoscopy in Japanese patients with low-dose-aspirin-associated gastroduodenal mucosal injury. United European Gastroenterology Journal 1(4): 259-264, 2014

A randomized, double-blind, placebo-controlled study of rebamipide for gastric mucosal injury taking aspirin with or without clopidogrel. Digestive Diseases and Sciences 59(8): 1885-1890, 2014

Prevention and treatment of gastric mucosal injury in patients taking low-dose aspirin. Nihon Rinsho. Japanese Journal of Clinical Medicine 69 Suppl 7: 450-454, 2012

Rebamipide, a mucoprotective drug, inhibits NSAIDs-induced gastric mucosal injury: possible involvement of the downregulation of 15-hydroxyprostaglandin dehydrogenase. Journal of Clinical Biochemistry and Nutrition 48(2): 149-153, 2011

Mucoprotective drugs and aspirin-induced gastric injury. Nihon Rinsho. Japanese Journal of Clinical Medicine 68(11): 2077-2082, 2011

Comparison of teprenone and famotidine against gastroduodenal mucosal damage in patients taking low-dose aspirin. Journal of Gastroenterology and Hepatology 29 Suppl 4(): 11-15, 2015

Endoscopic evidence of mucosal injury in patients taking ticlopidine compared with patients taking aspirin/nonsteroidal antiinflammatory drugs and controls. Journal of Clinical Gastroenterology 34(5): 529-532, 2002

Low-dose aspirin-induced gastroduodenal mucosal injury in Japanese patients with arteriosclerotic disease. Internal Medicine 49(23): 2537-2545, 2011

Effect of Helicobacter pylori eradication on anti-thrombotic dose aspirin-induced gastroduodenal mucosal injury. Journal of Gastroenterology and Hepatology 19(7): 773-777, 2004

Mo1265 Significance of atrophic Changes of Gastric Mucosa in Patients With Gastric Mucosal Injury in Low-Dose Aspirin Users. Gastroenterology 150(4): S682-S683, 2016

Relative contribution of mucosal injury and Helicobacter pylori in the development of gastroduodenal lesions in patients taking non-steroidal anti-inflammatory drugs. Gut 51(3): 336-343, September, 2002

Geographic differences in low-dose aspirin-associated gastroduodenal mucosal injury. World Journal of Gastroenterology 21(25): 7709-7717, 2016

Induced gastric mucosal apoptosis in Helicobacter pylori positive patients taking low dose aspirin A 6-month case-control study. Gastroenterology 120(5 Supplement 1): A 598, April, 2001